Successful exit of portfolio company and major invest in AI and digital health in early cancer detection, valued at CHF 23.3 million - Seite 2

Xlife Sciences investment introduces not only financial assets but also invaluable expertise, a vast network, and, through its alliance with FUSE-AI GmbH, access to cutting-edge AI solutions. These technological advancements will empower 4D Lifetec to combine diverse data sources, including patient records, genetic data, and imaging, ensuring exhaustive decision-making support for oncologists. The outcome? Enhanced precision in cancer diagnosis, ultimately boosting patient care standards and results.

Oliver R. Baumann, CEO of Xlife Sciences AG, voiced his eagerness about the partnership, stating, «We are excited to embark on this journey with 4D Lifetec. Together, we will lead the way in leveraging cutting-edge AI technologies to enhance healthcare solutions and redefine diagnostics.»

Dr. Giancarlo Rizzoli, CEO of 4D Lifetec, shared his vision, commenting, «The combined forces of 4D Lifetec and Xlife Sciences are a game changer, paving the way to new horizons in digital health. We look forward to our continued collaboration.»

Together, both entities share a collective mission on optimizing workflow dynamics, unlocking expansive growth avenues via digital health, and actively contributing to the progressive evolution of cancer diagnostics.

In addition, both companies extend heartfelt gratitude to stakeholders and shareholders for their relentless support. The closing is expected by end of November.

Financial calendar

Annual Report 2023                                                                                      23 April 2024

Annual Shareholders Meeting 2024                                                              20 June 2024

Half-Year Report 2024                                                                                   19 September 2024

 

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone [phone]
[e-mail], www.xlifesciences.ch, 
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange

Contact
 Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, [e-mail]